Mestastop and Immunobiome started their collaboration in October 2020. Precisely fifteen months down the line, they filed the provisional specification for their first patent; “Method for producing a spontaneous metastasis model”. The patent describes a way to create an orthotopic spontaneous metastasis model that evaluates metastasis in a short time of six weeks. The model has a greater than 90% take rate of metastasis and is a highly robust system monitored via live imaging.  

Highlighting the milestone, Prof. IM Sin-Hyeog, CEO of Immunobiome Inc, Korea, said; “Congratulations to Mestastop and Immunobiome on making huge progress in a short period. I hope we can make bigger progress in 2022 through in-depth collaboration.”

Dr Debabani Roy Chowdhury, co-Founder Mestastop, had the following comments; “It is indeed invigorating to see a lot of hard work come to some fruition, but there’s a long way to go. Next, we intend to extend this model into multiple solid cancers and then also into syngeneic mice, for immune relevant studies”. “This collaborative model will be a gamechanger for metastasis research”, she added.

Mestastop, a Biotech company registered from Bangalore, has created three unique solutions to progress metastasis focused drug discovery and early predictive diagnostics. They completed their fourth milestone in December 2021 by completing proof-of-concept studies on their first-in-class target for metastasis and validating a potential repurposed candidate for the clinic.

Immunobiome develops novel drug candidates targeting intractable immune diseases. Drug candidates include Active Pharmaceutical Ingredients (API) and Live Biotherapeutic Products (LBP) to enhance anti-cancer immunity or suppress inflammatory immune responses. Using an innovative Next Generation Immuno typing System of ImmunoBiome (Avatiome™), they have further identified key effector molecules from LBP candidates and defined their mechanisms of action. Currently, the team is developing two LBP candidates, IMB 001 and IMB 002, targeting cancer and inflammatory disorders. Phase 1b/2a clinical trial will be launched in 2022, targeting cancers.